Increased therapeutic efficacy of cis-platinum complexes of poly-L-glutamic acid against a murine carcinoma.
Cis-diamminedichloroplatinum(II) (cis-DDP) and cis diamminediaquoplatinum(II) nitrate (cis-aq) were complexed to poly-L-glutamic acid (PG) of Mr 13,000 or 58,000. Soluble complexes were formed by mixing the platinum(II) compounds with the PG preparations in water at a molar ratio of one platinum(II) to 5 glutamyl residues of the PG. Compared to free cis-DDP, the complexes were about 2 to 6 times less cytotoxic to F9 embryonal carcinoma cells in vitro. In vivo studies with this tumor indicated that when administered i.p. one day after the tumor cells, the complexes were somewhat less active than cis-DDP. However, in comparison to the free drug which, due to its toxicity, was effective only within a very narrow dose range, the complexes were much less toxic, manifesting a wide therapeutic range in which no mortality occurred either from the tumor or as a result of the toxic effects of the drug. Cis-DDP and cis-aq complexes of PG Mr-58,000 were somewhat more toxic than the complexes of PG Mr, 13,000. The in vivo anti-tumor activity of most complexes was superior to that of free cis-DDP when tested in mice carrying high tumor loads. Due to their wide therapeutic range, the complexes could be given at high drug doses resulting in increased life span of the tumor-bearing mice. Moreover, 3 repeated injections of these high doses did not cause death from toxicity and resulted in partial or total eradication of advanced tumors.
D000818:Animals; D002460:Cell Line; D002945:Cisplatin / Q000008:administration & dosage* / Q000633:toxicity; D005260:Female; D066298:In Vitro Techniques; D051379:Mice; D008807:Mice, Inbred BALB C; D009373:Neoplasms, Germ Cell and Embryonal / Q000188:drug therapy*; D010455:Peptides / Q000008:administration & dosage*; D011099:Polyglutamic Acid / Q000008:administration & dosage*
D010455:Peptides; D011099:Polyglutamic Acid; D002945:Cisplatin